Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression. (CERES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03059355
Recruitment Status : Recruiting
First Posted : February 23, 2017
Last Update Posted : August 6, 2019
Sponsor:
Information provided by (Responsible Party):
Joshua M Hare, University of Miami

Brief Summary:
This study is to compare the safety and efficacy of UCMSCs and BMMSCs administered intravenously in patients to evaluate cytokine suppression in patients with chronic inflammation. Cells administered via intravenous infusion (IV) and will be tested in 37 patients in two phases (Pilot and Randomized).

Condition or disease Intervention/treatment Phase
Endothelial Dysfunction Metabolic Syndrome Chronic Inflammation Biological: UCMSCs Biological: BMMSCs Other: Placebo Phase 1 Phase 2

Detailed Description:

In this Study, cells administered via intravenous infusion (IV) will be tested in 37 patients in two phases (Pilot and Randomized):

The pilot phase will consist of 12 subjects and the randomized phase will consist of 25 subjects.

Subjects in each pilot phase group (Group 1, 2, 3 and 4) will not be treated less than 5 days apart and will each undergo full evaluation post infusion to demonstrate there is no evidence of treatment emergent SAE's prior to proceeding with the treatment of further subjects.

For subjects randomized to Group 3, 4, C and D (BMMSCs); the cells will be derived from a sample of the subject's bone marrow (obtained by iliac crest aspiration) approximately 4-6 weeks prior to infusion.

Duration of Study Participation will be 12 months (Follow-up will be at 2 weeks, 1 Month, 3, 6, and 12 months.)


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Randomized, Placebo-controlled Comparative Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Bone Marrow (BM) Derived MSCs to Evaluate Cytokine Suppression in Patients With Chronic Inflammation Due to Metabolic Syndrome.
Actual Study Start Date : April 12, 2018
Estimated Primary Completion Date : June 2025
Estimated Study Completion Date : June 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Pilot Phase: Group 1 (UCMSCs)
Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
Biological: UCMSCs
Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)

Experimental: Pilot Phase: Group 2 (UCMSCs - 100 million)
Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
Biological: UCMSCs
Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)

Experimental: Pilot Phase: Group 3 (BMMSCs - 20 million)
Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
Biological: BMMSCs
Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)

Experimental: Pilot Phase: Group 4 (BMMSCs -100 million)
Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.
Biological: BMMSCs
Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)

Experimental: Group A (UCMSCs - 20 Million)
Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
Biological: UCMSCs
Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)

Experimental: Group B (UCMSCs - 100 million)
Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
Biological: UCMSCs
Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)

Experimental: Group C (BMMSCs - 20 million)
Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
Biological: BMMSCs
Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)

Experimental: Group D (BMMSCs - 100 million)
Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.
Biological: BMMSCs
Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)

Placebo Comparator: Group E (Placebo)
Five (5) subjects will be treated with a single administration of placebo delivered via peripheral intravenous infusion.
Other: Placebo
a single administration of placebo delivered via peripheral intravenous infusion.




Primary Outcome Measures :
  1. Incidence of any treatment-emergent serious adverse events (TE-SAEs) [ Time Frame: one month post infusion ]
    Incidence (at one-month post infusion) of any treatment-emergent serious adverse events (TE-SAEs), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities, determined per the Investigator's judgment.


Secondary Outcome Measures :
  1. Change of inflammatory markers [ Time Frame: Baseline and at 6 months ]
    Change between baseline and 6 months for the following panel of inflammatory markers: C-reactive protein, Interleukin-6, D-dimer, fibrinogen, Complete blood count with differential, and TNFα.

  2. Effect on Frailty Phenotype Score [ Time Frame: baseline, 3 and 6 months' follow-up visits ]
    to measure if intervention with UCMSCs versus BMMSCs has a beneficial effect on Cardiovascular Health Study (CHS) Frailty Phenotype Score.

  3. Effect on Physical Performance through Quality of Life questionnaires [ Time Frame: baseline, 3 and 6 months' follow-up visits ]
    to measure if intervention with UCMSCs versus BMMSCs has a beneficial effect on physical performance by comparing quality of life questionnaires.

  4. Change of Pro-inflammatory cytokines in laboratory analysis [ Time Frame: baseline, 3 and 6 months' follow-up visits ]

    to measure if intervention with UCMSCs versus BMMSCs reduces pro-inflammatory cytokines, and the relationship between these cytokines.

    Assess change for the following panel of inflammatory markers: CRP, IL-6, D-dimer, fibrinogen, CBC with differential, and TNFα.


  5. Determine if there is an improvement in symptoms between subjects receiving umbilical cord cells versus bone marrow cells [ Time Frame: baseline, 3 and 6 months' follow-up visits ]
    to measure if intervention with UCMSCs versus BMMSCs improves composite clinical outcomes / symptoms in congestive heart failure subjects.

  6. Number of study participants experiencing safety events (difference between dose and placebo subjects) [ Time Frame: baseline, 3 and 6 months' follow-up visits ]
    To measure the safety of three doses of UCMSCs versus BMMSCs compared to placebo in congestive heart failure.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provide written informed consent
  • Subjects age >21(greater than or equal to 21) and < 85 (less than or equal to 85 years at the time of signing the Informed Consent Form.
  • Show signs of cytokine suppression
  • Each subject must have endothelial dysfunction.
  • At the time of enrollment, each subject must meet at least 3 out of the 5 criteria under the harmonized definition of the metabolic syndrome, consisting of the following:

    • Hypertension
    • Elevated triglycerides
    • Reduced high-density lipoprotein (HDL) levels
    • Elevated fasting glucose
    • Apple shaped adiposity

Exclusion Criteria:

  • Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.
  • Inability to perform any of the assessments required for endpoint analysis.
  • Active listing (or expected future listing) for transplant of any organ.
  • Clinically important abnormal screening laboratory values, as determined by the P.I.
  • Serious comorbid illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.
  • Have known allergies to penicillin or streptomycin.
  • Hypersensitivity to dimethyl sulfoxide (DMSO).
  • Be an organ transplant recipient.
  • Have a clinical history of malignancy within 3 years (i.e., subjects with prior malignancy must be disease free for 3 years), except curatively- treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma, if recurrence occurs.
  • Have a non-pulmonary condition that limits lifespan to < 1 year.
  • Have a history of drug or alcohol abuse within the past 24 months.
  • Be serum positive for HIV, hepatitis BsAg or Viremic hepatitis C, and/or Syphilis - VDRL (Confirmation with FTA-ABS if needed (Syphilis)).
  • Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
  • Patients with EF<45% (heart failure patients).
  • GFR < or equal to 35 (chronic kidney disease stage 3 or higher).
  • Liver disease (elevated LFTs greater than 3x normal limit).
  • Advanced pulmonary disease (requiring home oxygen and/or less than 1 expected life span).
  • Proliferative diabetic retinopathy
  • Hemoglobin A1C greater than 7.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03059355


Contacts
Layout table for location contacts
Contact: Joshua M Hare, MD 305-243-5579 jhare@med.miami.edu

Locations
Layout table for location information
United States, Florida
ISCI / University of Miami Miller School of Medicine Recruiting
Miami, Florida, United States, 33136
Contact: Joshua M Hare, MD    305-243-5579    jhare@med.miami.edu   
Contact: Coordinators    305-243-7444    ISCIStudyInfo@miami.edu   
Principal Investigator: Joshua M Hare, MD         
Sponsors and Collaborators
Joshua M Hare
Investigators
Layout table for investigator information
Principal Investigator: Joshua M Hare, MD ISCI / University of Miami Miller School of Medicine

Additional Information:
Layout table for additonal information
Responsible Party: Joshua M Hare, Director of ISCI, Louis Lemberg Professor of Medicine, University of Miami
ClinicalTrials.gov Identifier: NCT03059355     History of Changes
Other Study ID Numbers: 20170095
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Syndrome
Inflammation
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases